Positron emission tomography (PET) study with [18F]AZD4694 and [11C]AZD2184, candidate PET ligands for Aβ Amyloid - PET

Exclusion Criteria

• - Alzheimer's Disease patients - Clinically significant illness the 2 weeks prior to the administration of the PET ligand
• - Significant cerebrovascular disease or depression, central nervous system infarct or infection or lesions
• - Administration of any investigational product within 3 months prior to study and/or PET measurements for scientific purposes within the last 12 months.
• - Healthy volunteers - clinically significant illness within 2 weeks before administration of PET ligand, history of psychiatric or somatic disease/condition that may interfere, first degree relative with dementia. Obvious deterioration of memory functions.